Effective reduction of unnecessary biopsies through a deep-learning-assisted aggressive prostate cancer detector.

Journal: Scientific reports
PMID:

Abstract

Despite being one of the most prevalent cancers, prostate cancer (PCa) shows a significantly high survival rate, provided there is timely detection and treatment. Currently, several screening and diagnostic tests are required to be carried out in order to detect PCa. These tests are often invasive, requiring either a biopsy (Gleason score and ISUP) or blood tests (PSA). Computational methods have been shown to help this process, using multiparametric MRI (mpMRI) data to detect PCa, effectively providing value during the diagnosis and monitoring stages. While delineating lesions requires a high degree of experience and expertise from the radiologists, being subject to a high degree of inter-observer variability, often leading to inconsistent readings, these computational models can leverage the information from mpMRI to locate the lesions with a high degree of certainty. By considering as positive samples only those that have an ISUP≥2 we can train aggressive index lesion detection models. The main advantage of this approach is that, by focusing only on aggressive disease, the output of such a model can also be seen as an indication for biopsy, effectively reducing unnecessary biopsy screenings. In this work, we utilize both the highly heterogeneous ProstateNet dataset, and the PI-CAI dataset, to develop accurate aggressive disease detection models.

Authors

  • Nuno M Rodrigues
    LASIGE, Department of Informatics, Faculty of Sciences, University of Lisbon, Lisbon, Portugal.
  • José Guilherme de Almeida
    Champalimaud Foundation, Lisbon, Portugal. jose.almeida@research.fchampalimaud.org.
  • Ana Sofia Castro Verde
    Computational Clinical Imaging Group, Champalimaud Foundation, Lisbon, Portugal.
  • Ana Mascarenhas Gaivão
    Radiology Department, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
  • Carlos Bireiro
    Radiology Department, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
  • Inês Santiago
    Radiology Department, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
  • Joana Ip
    Radiology Department, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
  • Sara Belião
    Radiology Department, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal.
  • Celso Matos
    Champalimaud Foundation, Lisbon, Portugal.
  • Leonardo Vanneschi
    NOVA IMS, Universidade Nova de Lisboa, 1070-312 Lisboa, Portugal.
  • Manolis Tsiknakis
    Computational BioMedicine Laboratory, FORTH-ICS, Heraklion, Crete, Greece.
  • Kostas Marias
    Computational BioMedicine Laboratory, FORTH-ICS, Heraklion, Crete, Greece.
  • Daniele Regge
    From the 3D Imaging Research Lab, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, 25 New Chardon St, Suite 400C, Boston, MA 02114 (R.T., J.J.N., N.K., T.H., H.Y.); Department of Information Science and Technology, National Institute of Technology, Oshima College, Yamaguchi, Japan (R.T.); Department of Medical Physics and Engineering, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan (J.O.); Department of Medical Physics, University of Applied Sciences Giessen, Giessen, Germany (N.K.); Department of Radiology, Seoul National University Hospital, Seoul, Republic of Korea (S.H.K.); Department of Surgical Sciences, University of Torino, Turin, Italy (D.R.); and Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-Istituto di Ricovero e Cura a Carattere Scientifico (FPO-IRCCS), Candiolo, Turin, Italy (D.R.).
  • Sara Silva
    LASIGE, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal.
  • Nickolas Papanikolaou
    Champalimaud Foundation, Lisbon, Portugal.